MethylGene Announces the Appointment of Peggy Mulligan
News Mar 22, 2012
MethylGene Inc. has announced the appointment of Peggy Mulligan, FCA to the Company's Board of Directors.
"Peggy is a financial and audit expert, and a well respected business leader. We look forward to her guidance as we plan for the future", said Charles Grubsztajn, President and CEO of MethylGene.
Peggy most recently served as Executive Vice President and Chief Financial Officer of Valeant Pharmaceuticals International, Inc (formerly Biovail Corporation), a multinational pharmaceutical company listed on both the New York Stock Exchange and Toronto Stock Exchange.
During her tenure, she co-led the merger and subsequent integration with Valeant Pharmaceuticals International, Inc. She is currently a member of the Board of Directors of Ontario Power Generation Inc. ("OPG") and Chair of OPG's Human Resources & Compensation Committee.
From 2005 to 2007 Peggy served as Executive Vice President, Chief Financial Officer and Treasurer of Linamar Corporation.
Previously Peggy spent eleven years in various roles at the Bank of Nova Scotia, most recently as Executive Vice President, Systems & Operations.
Before joining the Bank of Nova Scotia she was an Audit Partner with Price Waterhouse. In 2003 and 2004 Ms. Mulligan was named one of Canada's Top 100 Most Powerful Women by the Women's Executive Network.
She holds a B. Math (Honours) from the University of Waterloo and she is a Fellow of the Institute of Chartered Accountants (FCA) of Ontario.
Immune Response Restored in Patients with Melanoma Thanks to New CompoundNews
A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017.READ MORE
Commonly Prescribed Painkillers: What Can be Done to Reduce Risk of Obesity and Sleep Deprivation?News
Commonly prescribed painkillers need to be given for shorter periods of time to reduce the risk of obesity and sleep deprivation, a new study has revealed.READ MORE